Global Hormone Refractory Prostate Cancer (HRPCA) Market Growth (Status and Outlook) 2022-2028
- LP 4853802
- 60 Pages
- February 2022
- Pharmaceuticals
The United States Hormone Refractory Prostate Cancer (HRPCA) market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Hormone Refractory Prostate Cancer (HRPCA) market, reaching US$ million by the year 2028. As for the Europe Hormone Refractory Prostate Cancer (HRPCA) landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Hormone Refractory Prostate Cancer (HRPCA) players cover Astellas Inc, Sanofi S.A, Dendreon Corporation, Bayer AG, and Johnson & Johnson, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Hormone Refractory Prostate Cancer (HRPCA) market by product type, application, key players and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022 in Section 2.3; and forecast to 2028 in section 10.7.
Cytotoxic Agents
Anti-Androgens
Vaccines
Radio-Pharmaceuticals
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 10.8.
Hospitals
Ambulatory Surgical Centers
Specialty Clinics
Others
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report: Breakdown data in in Chapter 3.
Astellas Inc
Sanofi S.A
Dendreon Corporation, Bayer AG
Johnson & Johnson
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size 2017-2028
2.1.2 Hormone Refractory Prostate Cancer (HRPCA) Market Size CAGR by Region 2017 VS 2022 VS 2028
2.2 Hormone Refractory Prostate Cancer (HRPCA) Segment by Type
2.2.1 Cytotoxic Agents
2.2.2 Anti-Androgens
2.2.3 Vaccines
2.2.4 Radio-Pharmaceuticals
2.3 Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type
2.3.1 Hormone Refractory Prostate Cancer (HRPCA) Market Size CAGR by Type (2017 VS 2022 VS 2028)
2.3.2 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Market Share by Type (2017-2022)
2.4 Hormone Refractory Prostate Cancer (HRPCA) Segment by Application
2.4.1 Hospitals
2.4.2 Ambulatory Surgical Centers
2.4.3 Specialty Clinics
2.4.4 Others
2.5 Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application
2.5.1 Hormone Refractory Prostate Cancer (HRPCA) Market Size CAGR by Application (2017 VS 2022 VS 2028)
2.5.2 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Market Share by Application (2017-2022)
3 Hormone Refractory Prostate Cancer (HRPCA) Market Size by Player
3.1 Hormone Refractory Prostate Cancer (HRPCA) Market Size Market Share by Players
3.1.1 Global Hormone Refractory Prostate Cancer (HRPCA) Revenue by Players (2020-2022)
3.1.2 Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Players (2020-2022)
3.2 Global Hormone Refractory Prostate Cancer (HRPCA) Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Hormone Refractory Prostate Cancer (HRPCA) by Regions
4.1 Hormone Refractory Prostate Cancer (HRPCA) Market Size by Regions (2017-2022)
4.2 Americas Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth (2017-2022)
4.3 APAC Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth (2017-2022)
4.4 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth (2017-2022)
4.5 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth (2017-2022)
5 Americas
5.1 Americas Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2017-2022)
5.2 Americas Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2017-2022)
5.3 Americas Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2017-2022)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region (2017-2022)
6.2 APAC Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2017-2022)
6.3 APAC Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2017-2022)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Hormone Refractory Prostate Cancer (HRPCA) by Country (2017-2022)
7.2 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2017-2022)
7.3 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2017-2022)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) by Region (2017-2022)
8.2 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2017-2022)
8.3 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2017-2022)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Hormone Refractory Prostate Cancer (HRPCA) Market Forecast
10.1 Global Hormone Refractory Prostate Cancer (HRPCA) Forecast by Regions (2023-2028)
10.1.1 Global Hormone Refractory Prostate Cancer (HRPCA) Forecast by Regions (2023-2028)
10.1.2 Americas Hormone Refractory Prostate Cancer (HRPCA) Forecast
10.1.3 APAC Hormone Refractory Prostate Cancer (HRPCA) Forecast
10.1.4 Europe Hormone Refractory Prostate Cancer (HRPCA) Forecast
10.1.5 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Forecast
10.2 Americas Hormone Refractory Prostate Cancer (HRPCA) Forecast by Country (2023-2028)
10.2.1 United States Hormone Refractory Prostate Cancer (HRPCA) Market Forecast
10.2.2 Canada Hormone Refractory Prostate Cancer (HRPCA) Market Forecast
10.2.3 Mexico Hormone Refractory Prostate Cancer (HRPCA) Market Forecast
10.2.4 Brazil Hormone Refractory Prostate Cancer (HRPCA) Market Forecast
10.3 APAC Hormone Refractory Prostate Cancer (HRPCA) Forecast by Region (2023-2028)
10.3.1 China Hormone Refractory Prostate Cancer (HRPCA) Market Forecast
10.3.2 Japan Hormone Refractory Prostate Cancer (HRPCA) Market Forecast
10.3.3 Korea Hormone Refractory Prostate Cancer (HRPCA) Market Forecast
10.3.4 Southeast Asia Hormone Refractory Prostate Cancer (HRPCA) Market Forecast
10.3.5 India Hormone Refractory Prostate Cancer (HRPCA) Market Forecast
10.3.6 Australia Hormone Refractory Prostate Cancer (HRPCA) Market Forecast
10.4 Europe Hormone Refractory Prostate Cancer (HRPCA) Forecast by Country (2023-2028)
10.4.1 Germany Hormone Refractory Prostate Cancer (HRPCA) Market Forecast
10.4.2 France Hormone Refractory Prostate Cancer (HRPCA) Market Forecast
10.4.3 UK Hormone Refractory Prostate Cancer (HRPCA) Market Forecast
10.4.4 Italy Hormone Refractory Prostate Cancer (HRPCA) Market Forecast
10.4.5 Russia Hormone Refractory Prostate Cancer (HRPCA) Market Forecast
10.5 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Forecast by Region (2023-2028)
10.5.1 Egypt Hormone Refractory Prostate Cancer (HRPCA) Market Forecast
10.5.2 South Africa Hormone Refractory Prostate Cancer (HRPCA) Market Forecast
10.5.3 Israel Hormone Refractory Prostate Cancer (HRPCA) Market Forecast
10.5.4 Turkey Hormone Refractory Prostate Cancer (HRPCA) Market Forecast
10.5.5 GCC Countries Hormone Refractory Prostate Cancer (HRPCA) Market Forecast
10.6 Global Hormone Refractory Prostate Cancer (HRPCA) Forecast by Type (2023-2028)
10.7 Global Hormone Refractory Prostate Cancer (HRPCA) Forecast by Application (2023-2028)
11 Key Players Analysis
11.1 Astellas Inc
11.1.1 Astellas Inc Company Information
11.1.2 Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Product Offered
11.1.3 Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Revenue, Gross Margin and Market Share (2020-2022)
11.1.4 Astellas Inc Main Business Overview
11.1.5 Astellas Inc Latest Developments
11.2 Sanofi S.A
11.2.1 Sanofi S.A Company Information
11.2.2 Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Product Offered
11.2.3 Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Revenue, Gross Margin and Market Share (2020-2022)
11.2.4 Sanofi S.A Main Business Overview
11.2.5 Sanofi S.A Latest Developments
11.3 Dendreon Corporation, Bayer AG
11.3.1 Dendreon Corporation, Bayer AG Company Information
11.3.2 Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Product Offered
11.3.3 Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Revenue, Gross Margin and Market Share (2020-2022)
11.3.4 Dendreon Corporation, Bayer AG Main Business Overview
11.3.5 Dendreon Corporation, Bayer AG Latest Developments
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Information
11.4.2 Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Product Offered
11.4.3 Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Revenue, Gross Margin and Market Share (2020-2022)
11.4.4 Johnson & Johnson Main Business Overview
11.4.5 Johnson & Johnson Latest Developments
12 Research Findings and Conclusion
Table 1. Hormone Refractory Prostate Cancer (HRPCA) Market Size CAGR by Region (2017 VS 2022 VS 2028) & ($ Millions)
Table 2. Major Players of Cytotoxic Agents
Table 3. Major Players of Anti-Androgens
Table 4. Major Players of Vaccines
Table 5. Major Players of Radio-Pharmaceuticals
Table 6. Hormone Refractory Prostate Cancer (HRPCA) Market Size CAGR by Type (2017 VS 2022 VS 2028) & ($ Millions)
Table 7. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2017-2022) & ($ Millions)
Table 8. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Market Share by Type (2017-2022)
Table 9. Hormone Refractory Prostate Cancer (HRPCA) Market Size CAGR by Application (2017 VS 2022 VS 2028) & ($ Millions)
Table 10. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2017-2022) & ($ Millions)
Table 11. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Market Share by Application (2017-2022)
Table 12. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue by Players (2020-2022) & ($ Millions)
Table 13. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Player (2020-2022)
Table 14. Hormone Refractory Prostate Cancer (HRPCA) Key Players Head office and Products Offered
Table 15. Hormone Refractory Prostate Cancer (HRPCA) Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 16. New Products and Potential Entrants
Table 17. Mergers & Acquisitions, Expansion
Table 18. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Regions 2017-2022 & ($ Millions)
Table 19. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Market Share by Regions (2017-2022)
Table 20. Americas Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2017-2022) & ($ Millions)
Table 21. Americas Hormone Refractory Prostate Cancer (HRPCA) Market Size Market Share by Country (2017-2022)
Table 22. Americas Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2017-2022) & ($ Millions)
Table 23. Americas Hormone Refractory Prostate Cancer (HRPCA) Market Size Market Share by Type (2017-2022)
Table 24. Americas Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2017-2022) & ($ Millions)
Table 25. Americas Hormone Refractory Prostate Cancer (HRPCA) Market Size Market Share by Application (2017-2022)
Table 26. APAC Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region (2017-2022) & ($ Millions)
Table 27. APAC Hormone Refractory Prostate Cancer (HRPCA) Market Size Market Share by Region (2017-2022)
Table 28. APAC Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2017-2022) & ($ Millions)
Table 29. APAC Hormone Refractory Prostate Cancer (HRPCA) Market Size Market Share by Type (2017-2022)
Table 30. APAC Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2017-2022) & ($ Millions)
Table 31. APAC Hormone Refractory Prostate Cancer (HRPCA) Market Size Market Share by Application (2017-2022)
Table 32. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2017-2022) & ($ Millions)
Table 33. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size Market Share by Country (2017-2022)
Table 34. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2017-2022) & ($ Millions)
Table 35. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size Market Share by Type (2017-2022)
Table 36. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2017-2022) & ($ Millions)
Table 37. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size Market Share by Application (2017-2022)
Table 38. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region (2017-2022) & ($ Millions)
Table 39. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size Market Share by Region (2017-2022)
Table 40. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2017-2022) & ($ Millions)
Table 41. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size Market Share by Type (2017-2022)
Table 42. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2017-2022) & ($ Millions)
Table 43. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size Market Share by Application (2017-2022)
Table 44. Key Market Drivers & Growth Opportunities of Hormone Refractory Prostate Cancer (HRPCA)
Table 45. Key Market Challenges & Risks of Hormone Refractory Prostate Cancer (HRPCA)
Table 46. Key Industry Trends of Hormone Refractory Prostate Cancer (HRPCA)
Table 47. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Forecast by Regions (2023-2028) & ($ Millions)
Table 48. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Market Share Forecast by Regions (2023-2028)
Table 49. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Forecast by Type (2023-2028) & ($ Millions)
Table 50. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Market Share Forecast by Type (2023-2028)
Table 51. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Forecast by Application (2023-2028) & ($ Millions)
Table 52. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Market Share Forecast by Application (2023-2028)
Table 53. Astellas Inc Details, Company Type, Hormone Refractory Prostate Cancer (HRPCA) Area Served and Its Competitors
Table 54. Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Product Offered
Table 55. Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 56. Astellas Inc Main Business
Table 57. Astellas Inc Latest Developments
Table 58. Sanofi S.A Details, Company Type, Hormone Refractory Prostate Cancer (HRPCA) Area Served and Its Competitors
Table 59. Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Product Offered
Table 60. Sanofi S.A Main Business
Table 61. Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 62. Sanofi S.A Latest Developments
Table 63. Dendreon Corporation, Bayer AG Details, Company Type, Hormone Refractory Prostate Cancer (HRPCA) Area Served and Its Competitors
Table 64. Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Product Offered
Table 65. Dendreon Corporation, Bayer AG Main Business
Table 66. Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 67. Dendreon Corporation, Bayer AG Latest Developments
Table 68. Johnson & Johnson Details, Company Type, Hormone Refractory Prostate Cancer (HRPCA) Area Served and Its Competitors
Table 69. Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Product Offered
Table 70. Johnson & Johnson Main Business
Table 71. Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 72. Johnson & Johnson Latest Developments
List of Figures
Figure 1. Hormone Refractory Prostate Cancer (HRPCA) Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate 2017-2028 ($ Millions)
Figure 6. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Market Share by Type in 2021
Figure 7. Hormone Refractory Prostate Cancer (HRPCA) in Hospitals
Figure 8. Global Hormone Refractory Prostate Cancer (HRPCA) Market: Hospitals (2017-2022) & ($ Millions)
Figure 9. Hormone Refractory Prostate Cancer (HRPCA) in Ambulatory Surgical Centers
Figure 10. Global Hormone Refractory Prostate Cancer (HRPCA) Market: Ambulatory Surgical Centers (2017-2022) & ($ Millions)
Figure 11. Hormone Refractory Prostate Cancer (HRPCA) in Specialty Clinics
Figure 12. Global Hormone Refractory Prostate Cancer (HRPCA) Market: Specialty Clinics (2017-2022) & ($ Millions)
Figure 13. Hormone Refractory Prostate Cancer (HRPCA) in Others
Figure 14. Global Hormone Refractory Prostate Cancer (HRPCA) Market: Others (2017-2022) & ($ Millions)
Figure 15. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Market Share by Application in 2021
Figure 16. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Player in 2021
Figure 17. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Market Share by Regions (2017-2022)
Figure 18. Americas Hormone Refractory Prostate Cancer (HRPCA) Market Size 2017-2022 ($ Millions)
Figure 19. APAC Hormone Refractory Prostate Cancer (HRPCA) Market Size 2017-2022 ($ Millions)
Figure 20. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size 2017-2022 ($ Millions)
Figure 21. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size 2017-2022 ($ Millions)
Figure 22. Americas Hormone Refractory Prostate Cancer (HRPCA) Value Market Share by Country in 2021
Figure 23. Americas Hormone Refractory Prostate Cancer (HRPCA) Consumption Market Share by Type in 2021
Figure 24. Americas Hormone Refractory Prostate Cancer (HRPCA) Market Size Market Share by Application in 2021
Figure 25. United States Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth 2017-2022 ($ Millions)
Figure 26. Canada Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth 2017-2022 ($ Millions)
Figure 27. Mexico Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth 2017-2022 ($ Millions)
Figure 28. Brazil Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth 2017-2022 ($ Millions)
Figure 29. APAC Hormone Refractory Prostate Cancer (HRPCA) Market Size Market Share by Region in 2021
Figure 30. APAC Hormone Refractory Prostate Cancer (HRPCA) Market Size Market Share by Application in 2021
Figure 31. China Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth 2017-2022 ($ Millions)
Figure 32. Japan Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth 2017-2022 ($ Millions)
Figure 33. Korea Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth 2017-2022 ($ Millions)
Figure 34. Southeast Asia Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth 2017-2022 ($ Millions)
Figure 35. India Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth 2017-2022 ($ Millions)
Figure 36. Australia Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth 2017-2022 ($ Millions)
Figure 37. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size Market Share by Country in 2021
Figure 38. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size Market Share by Type in 2021
Figure 39. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size Market Share by Application in 2021
Figure 40. Germany Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth 2017-2022 ($ Millions)
Figure 41. France Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth 2017-2022 ($ Millions)
Figure 42. UK Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth 2017-2022 ($ Millions)
Figure 43. Italy Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth 2017-2022 ($ Millions)
Figure 44. Russia Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth 2017-2022 ($ Millions)
Figure 45. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size Market Share by Region in 2021
Figure 46. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size Market Share by Type in 2021
Figure 47. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size Market Share by Application in 2021
Figure 48. Egypt Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth 2017-2022 ($ Millions)
Figure 49. South Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth 2017-2022 ($ Millions)
Figure 50. Israel Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth 2017-2022 ($ Millions)
Figure 51. Turkey Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth 2017-2022 ($ Millions)
Figure 52. GCC Country Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth 2017-2022 ($ Millions)
Figure 53. Americas Hormone Refractory Prostate Cancer (HRPCA) Market Size 2023-2028 ($ Millions)
Figure 54. APAC Hormone Refractory Prostate Cancer (HRPCA) Market Size 2023-2028 ($ Millions)
Figure 55. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size 2023-2028 ($ Millions)
Figure 56. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size 2023-2028 ($ Millions)
Figure 57. United States Hormone Refractory Prostate Cancer (HRPCA) Market Size 2023-2028 ($ Millions)
Figure 58. Canada Hormone Refractory Prostate Cancer (HRPCA) Market Size 2023-2028 ($ Millions)
Figure 59. Mexico Hormone Refractory Prostate Cancer (HRPCA) Market Size 2023-2028 ($ Millions)
Figure 60. Brazil Hormone Refractory Prostate Cancer (HRPCA) Market Size 2023-2028 ($ Millions)
Figure 61. China Hormone Refractory Prostate Cancer (HRPCA) Market Size 2023-2028 ($ Millions)
Figure 62. Japan Hormone Refractory Prostate Cancer (HRPCA) Market Size 2023-2028 ($ Millions)
Figure 63. Korea Hormone Refractory Prostate Cancer (HRPCA) Market Size 2023-2028 ($ Millions)
Figure 64. Southeast Asia Hormone Refractory Prostate Cancer (HRPCA) Market Size 2023-2028 ($ Millions)
Figure 65. India Hormone Refractory Prostate Cancer (HRPCA) Market Size 2023-2028 ($ Millions)
Figure 66. Australia Hormone Refractory Prostate Cancer (HRPCA) Market Size 2023-2028 ($ Millions)
Figure 67. Germany Hormone Refractory Prostate Cancer (HRPCA) Market Size 2023-2028 ($ Millions)
Figure 68. France Hormone Refractory Prostate Cancer (HRPCA) Market Size 2023-2028 ($ Millions)
Figure 69. UK Hormone Refractory Prostate Cancer (HRPCA) Market Size 2023-2028 ($ Millions)
Figure 70. Italy Hormone Refractory Prostate Cancer (HRPCA) Market Size 2023-2028 ($ Millions)
Figure 71. Russia Hormone Refractory Prostate Cancer (HRPCA) Market Size 2023-2028 ($ Millions)
Figure 72. Spain Hormone Refractory Prostate Cancer (HRPCA) Market Size 2023-2028 ($ Millions)
Figure 73. Egypt Hormone Refractory Prostate Cancer (HRPCA) Market Size 2023-2028 ($ Millions)
Figure 74. South Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size 2023-2028 ($ Millions)
Figure 75. Israel Hormone Refractory Prostate Cancer (HRPCA) Market Size 2023-2028 ($ Millions)
Figure 76. Turkey Hormone Refractory Prostate Cancer (HRPCA) Market Size 2023-2028 ($ Millions)
Figure 77. GCC Countries Hormone Refractory Prostate Cancer (HRPCA) Market Size 2023-2028 ($ Millions)
Similar Reports
The United States pneumococcal & meningococcal vaccines market is set to surpass US$ 7.5 Million by the year end of 2025. “United States Pneumococcal & Meningococcal Vaccines Market by Company Profile, Deals Type, Brand Analysis, Share, Key Trends & Opportunities to 2025” presents an in–depth assessment of the United States pneumococcal & meningococcal vaccines market dynamics, opportunitie...
- Publish Date: June 24, 2019
- $1050
The global human immunodeficiency virus (HIV) drugs market size is expected to surpass US$ 30 billion by 2025. “Global Human Immunodeficiency Virus (HIV) Drugs Market 2019 – 2025: Top 22 Drugs Analysis, Key Trends, Players and Forecasts” presents an in-depth assessment of the global human immunodeficiency virus (HIV) drugs market dynamics, opportunities, future roadmap, competitive landscap...
- Publish Date: February 18, 2019
- $1290
The global 50 blockbuster drugs market size is estimated to reach a value of US$ 292 billion by 2025. ‘’Global Blockbuster Drugs Market 2015 - 2025: Top 50 Drugs Analysis, Deal Trends, Players and Forecasts” presents an in-depth assessment of the global blockbuster drugs market dynamics, opportunities, future roadmap, competitive landscape and discusses major trends. The report offers the m...
- Publish Date: December 11, 2018
- $1390
